REG - Renalytix PLC - Notice of GM

RenalytixAnnouncement

03/04/2024 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240403:nRSC2020Ja&default-theme=true

RNS Number : 2020J  Renalytix PLC  03 April 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Notice of General Meeting

 

LONDON and SALT LAKE CITY, April 3, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE:
RENX), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimising clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces that a General
Meeting ("GM") will be held on 22 April 2024 at 3.00 p.m. (BST) at 6 Stratton
Street Mayfair, London W1J 8LD.

 

A proxy statement (including the notice of GM) will be posted to shareholders
who have not consented to receive electronic communications later today and is
now available to view on the Company website:

 https://investors.renalytix.com/news-and-events/documents-and-presentations
(https://investors.renalytix.com/news-and-events/documents-and-presentations)

 

Hard copies of the form of proxy for the General Meeting will only be
available upon request and instead, voting can be done electronically using
the link www.signalshares.com (http://www.signalshares.com) . Investors will
need to log into their Signal Shares account or register if they have not
previously done so. All details about how to vote can be found in the notice
of GM.

 

To help with practical arrangements for the GM, any shareholder wishing to
attend is requested to register first by contacting Walbrook PR via email at
renalytix@walbrookpr.com.

 

For further information, please contact:

 

 Renalytix plc                                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                             Via Walbrook PR

 Stifel (Nominated Adviser, Joint Broker)                          Tel: 020 7710 7600
 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 Investec Bank plc (Joint Broker)                                  Tel: 020 7597 4000
 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited                                               Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                                                   (http://renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                                     Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGZXLFBZZLBBBB